DR. JONATHAN DAVID BORTZ, M.D.
Osteopathic Medicine at Stanford Ave, Saint Louis, MO

2009003, Feb 5, 2009

Jul 31, 2008

12/183989

Jonathan David Bortz - Saint Louis MO, US
Michael Norman Grimshaw - Saint Louis MO, US

DRUGTECH CORPORATION - Wilmington DE

A61K 9/52, A61K 31/554, A61K 9/22, A61P 25/00

424457, 51421113, 424468

A method for treating a medical condition for which quetiapine is indicated in a subject comprises comprising orally administering to the subject quetiapine or a pharmaceutically acceptable salt thereof in a daily dosage amount effective to treat said condition; wherein the quetiapine or salt thereof is administered in one to a plurality of dosage forms collectively comprising (a) a major quetiapine component in immediate-release form in a sedative effective amount, administered not earlier than about 3 hours prior to the start of a sleep period; and (b) either (i) a minor quetiapine component in extended-release, delayed extended-release or delayed pulsed-release form, wherein time of administration and release properties of the minor component provide substantial onset of release of quetiapine therefrom not earlier than about 6 hours after the start of the sleep period, or (ii) a plurality of minor quetiapine components in immediate-release form, administered sequentially during a waking period following the sleep period but not earlier than about 6 hours after the start of the sleep period; said minor component or components collectively being administered in an anxiolytic effective amount insufficient to cause an unacceptable degree of sedation. A dosage form suitable for use in such a method is also provided.

2009003, Feb 5, 2009

Aug 20, 2008

12/195170

Jonathan David Bortz - Saint Louis MO, US

DRUGTECH CORPORATION - Wilmington DE

A61K 33/42, A61K 33/26, A61K 31/295, A61K 38/16, A61P 3/02

424604, 424646, 424647, 424648, 514502, 514 12

Compositions and methods for prevent, stabilize, reverse or treat disorders related to iron deficiency in a human or other animal. In a first embodiment, the composition includes about 10 mg to about 500 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; and about 5 mg to about 500 mg of one or more forms of an organic acid. In another embodiment, the composition includes about 50 to about 150 mg of one or more forms of iron, wherein at least one form of iron is an aspartic acid-glycine chelate of iron; about 50 to about 250 mg of one or more forms of an organic acid; about 150 to about 250 mg of one or more forms of ascorbic acid; about 0.5 mg to about 1.5 mg vitamin B12; about 50 to about 150 mg intrinsic factor; and about 0.5 mg to about 1.5 mg folic acid.

2008013, Jun 12, 2008

Dec 5, 2007

11/950989

Jonathan David Bortz - Saint Louis MO, US
R. Saul Levinson - Chesterfield MO, US
Jeremy Donald Wang - Frontenac MO, US
Jisheng Ge - Chesterfield MO, US

A61K 31/5513, A61K 31/4164, A61K 9/00, A61P 25/08, A61K 31/505

424434, 514221, 514269, 514386

This invention relates generally to pharmaceutical compositions for treating seizures, and, more particularly, to pharmaceutical compositions that are bioadherent to oral and/or nasal mucosa, comprise one or more anti-acute seizure agents, and can be used to treat one or more conditions selected from the group consisting of acute seizure, repetitive seizures, and status epilepticus. This invention also relates generally to methods for preparing such compositions, methods of treatment using such compositions, uses of such compositions to prepare medicaments, and kits comprising such compositions.

2006014, Jun 29, 2006

Jan 5, 2006

11/326979

Jonathan Bortz - Saint Louis MO, US
R. Levinson - Chesterfield MO, US
Mitchell Kirschner - St. Louis MO, US
Robert Cuca - Glen Carbon IL, US

DrugTech Corporation - Wilmington DE

A61K 31/7034, A61K 9/00

424400000, 514035000

A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

2009002, Jan 29, 2009

Nov 9, 2005

11/793517

Jonathan David Bortz - Saint Louis MO, US
Mitchell Kirschner - Saint Louis MO, US

DRUGTECH CORPORATION - Wilmington DE

A61K 33/26, A61K 31/375

424646

The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions used in the treatment of one or more diseases having iron deficiency associated therewith.

8425956, Apr 23, 2013

Jul 25, 2011

13/189893

R. Charles Thompson - Peterson UT, US
Clayton Ericson - Morgan UT, US
Stephen Ashmead - West Haven UT, US
Jonathan Bortz - Saint Louis MO, US

Albion International, Inc. - Clearfield UT

A23L 1/305

426 74, 426648, 426656

Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.

2008029, Dec 4, 2008

May 23, 2008

12/126575

Jonathan David Bortz - Saint Louis MO, US
Michael Grimshaw - Saint Louis MO, US
David F. Erkoboni - Pennington NJ, US

DRUGTECH CORPORATION - Wilmington DE

A61K 9/52, A61K 9/24, A61K 31/428, A61P 25/16

424457, 424472, 514367

The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration.

2008028, Nov 20, 2008

Apr 18, 2008

12/105878

Daniel J. Thompson - Saint Louis MO, US
Robert C. Cuca - Glen Carbon IL, US
Jonathan David Bortz - Saint Louis MO, US

DRUGTECH CORPORATION - Wilmington DE

A61K 31/58, A61P 15/00

514176

A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.

8007846, Aug 30, 2011

Jan 16, 2007

11/623476

R. Charles Thompson - Peterson UT, US
Clayton Ericson - Morgan UT, US
Stephen Ashmead - West Haven UT, US
Jonathan Bortz - Saint Louis MO, US

Albion International, Inc. - Clearfield UT

A23L 1/304

426 74, 426656

Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.

2008022, Sep 18, 2008

Feb 18, 2008

12/032964

Jonathan David Bortz - Saint Louis MO, US
Yury Lagoviyer - Olivette MO, US
Paul Timothy Brady - Saint Louis MO, US

DRUGTECH CORPORATION - Wilmington DE

A61K 9/14

424489

The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device.